Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
We confirmed the suitability of our two backbone viruses MVA-mCherry and MVA-GFP in a proof-of-concept study to rapidly generate candidate vaccines against MARV. However, further studies are warranted to characterize the protective efficacy of these recombinant MVA-MARV vaccines in other preclinical models and to evaluate them as vaccine candidates in humans.
Authors
- Verena Krähling (ORCID: https://orcid.org/0000-0001-8658-9626)
- Cornelius Rohde (ORCID: https://orcid.org/0000-0002-4752-8326)
- Georgia Kalodimou (ORCID: https://orcid.org/0009-0002-5468-2695)
- Gerd Sutter (ORCID: https://orcid.org/0000-0001-6143-082X)
- Alexandra Kupke (ORCID: https://orcid.org/0000-0001-8517-4779)
- Alina Tscherne (ORCID: https://orcid.org/0000-0001-6066-8246)
- Asisa Volz (ORCID: https://orcid.org/0000-0001-8757-3896)
- Astrid Freudenstein
- Stephan W. Becker (ORCID: https://orcid.org/0000-0002-6621-9350)
- Sylvia Jany
- Satendra Kumar
Institutions
- Philipps University of Marburg (DE)
- University of Veterinary Medicine Hannover, Foundation (DE)
- German Center for Infection Research (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Vaccines
- Published
- 2024-11-24
- DOI
- https://doi.org/10.3390/vaccines12121316
- Citations
- 4
- Primary Topic
- Viral Infections and Outbreaks Research
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- Deutsches Zentrum für Infektionsforschung